Modernizing and designing evaluation frameworks for connected sensor technologies in medicine.

Health policy Technology

Journal

NPJ digital medicine
ISSN: 2398-6352
Titre abrégé: NPJ Digit Med
Pays: England
ID NLM: 101731738

Informations de publication

Date de publication:
2020
Historique:
received: 21 10 2019
accepted: 11 02 2020
entrez: 21 3 2020
pubmed: 21 3 2020
medline: 21 3 2020
Statut: epublish

Résumé

This manuscript is focused on the use of connected sensor technologies, including wearables and other biosensors, for a wide range of health services, such as collecting digital endpoints in clinical trials and remotely monitoring patients in clinical care. The adoption of these technologies poses five risks that currently exceed our abilities to evaluate and secure these products: (1) validation, (2) security practices, (3) data rights and governance, (4) utility and usability; and (5) economic feasibility. In this manuscript we conduct a landscape analysis of emerging evaluation frameworks developed to better manage these risks, broadly in digital health. We then propose a framework specifically for connected sensor technologies. We provide a pragmatic guide for how to put this evaluation framework into practice, taking lessons from concepts in drug and nutrition labels to craft a connected sensor technology label.

Identifiants

pubmed: 32195372
doi: 10.1038/s41746-020-0237-3
pii: 237
pmc: PMC7070075
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

37

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© The Author(s) 2020.

Déclaration de conflit d'intérêts

Competing interestsJ.G. is an employee of HealthMode. M.D. is a co-inventor of the Cleveland Clinic’s MyLegacy intellectual property portfolio, now licensed to Family Care Path, Inc.; as part of this license, she is entitled to a share in both royalties and returns on equity. W.W., B.W. are advisors and equity-holders, and A.C., C.M., and M.S. are employees of Elektra Labs, a healthcare-security company working in digital medicine. W.W. is also an advisor for Koneksa Health, a consultant for Best Doctors, and has received research funding within the last 12 months from Pfizer and Genentech. The other authors declare no competing interests.

Références

NPJ Digit Med. 2019;2(1):
pubmed: 30868107
J Med Internet Res. 2019 Mar 19;21(3):e12568
pubmed: 30888323
Digit Biomark. 2019 May 9;3(2):31-71
pubmed: 32095767
JAMA. 2020 Jan 6;:
pubmed: 31904799
N Engl J Med. 2019 Sep 5;381(10):956-968
pubmed: 31483966
Clin Pharmacol Ther. 2019 Jul;106(1):25-27
pubmed: 31013350
JAMA Netw Open. 2019 Apr 5;2(4):e192542
pubmed: 31002321
Clin Transl Sci. 2019 May;12(3):247-256
pubmed: 30635980
PLoS One. 2015 Sep 17;10(9):e0138095
pubmed: 26379170

Auteurs

Andrea Coravos (A)

Elektra Labs, Boston, MA USA.
2Harvard-MIT Center for Regulatory Science, Boston, MA USA.
Digital Medicine Society (DiMe), Boston, MA USA.
Biohacking Village, Washington, DC USA.

Megan Doerr (M)

5Sage Bionetworks, Seattle, WA USA.

Jennifer Goldsack (J)

Digital Medicine Society (DiMe), Boston, MA USA.

Christine Manta (C)

Elektra Labs, Boston, MA USA.
Digital Medicine Society (DiMe), Boston, MA USA.

Mark Shervey (M)

Elektra Labs, Boston, MA USA.

Beau Woods (B)

Biohacking Village, Washington, DC USA.
I Am The Cavalry, Washington, DC USA.
7Atlantic Council, Washington, DC USA.

William A Wood (WA)

Digital Medicine Society (DiMe), Boston, MA USA.
8University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC USA.

Classifications MeSH